Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain

Abstract

to be 194.4 compared with 194.1 for the Alendronic acid group, which resulted in a difference of 0.33 QALYs. The total costs for the Zoledronic acid group and Alendronic acid group were LE 215,232 and LE 215,087 respectively. These costs yielded an ICER of LE 435 for the Zoledronic acid group. The odds ratio of zoledronic acid on vertebral & non-vertebral fractures was found to have the greatest impact on the results. ConClusions: Compared with our willingness-to-pay threshold stated by world health organization for middle and lower income countries, Zoledronic acid is cost-effective; and most likely to result in an ICER lower than the threshold limit. Thus, the new treatment (Zoledronic acid) should be recommended in the Ministry of health list.